Author

A. J. Chalmers

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Assay:bulk RNA-seq· 2 Research Focus:drug response / drug discovery· 2 Organism:human· 2 Assay:imaging· 2 Organism:mouse· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1

Frequent Co-Authors

K. Stevenson· 3 shared C. Cloix· 2 shared D. Koessinger· 2 shared M. R. Jackson· 2 shared S. K. Chahal· 2 shared A. F. Rupp· 1 shared A. Koessinger· 1 shared A. L. Koessinger· 1 shared

Activity by Year

2020-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

K. Stevenson

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

ClonoScreen3D: a novel three-dimensional clonogenic screening platform for identification of radiosensitizers for glioblastoma

M. R. Jackson, A. R. Richards, A.-B. A. Oladipupo, S. K. Chahal, S. Caragher, A. J. Chalmers, N. Gomez-Roman

ClonoScreen3D is a 3D clonogenic screening platform that identifies radiosensitizers for glioblastoma by testing drug-radiation interactions using patient-derived cell lines.

International Journal of Radiation Oncology*Biology*Physics · Sep 1, 2024Peer-reviewedCancer Biology

Increased apoptotic priming of glioblastoma enables therapeutic targeting by BH3-mimetics

A. Koessinger, D. Koessinger, K. Kinch, L. Martinez-Escardo, N. Paul, Y. Elmasry, G. Malviya, C. Cloix, K. Campbell, F. Bock, J. O'Prey, K. Stevenson, C. Nixon, M. Jackson, G. Ichim, , S. Tait

This study shows that glioblastoma (GBM) is highly sensitive to BH3-mimetics due to elevated anti-apoptotic BCL-xL and MCL-1 expression, which can be therapeutically targeted.

bioRxiv · Jun 13, 2021 · PreprintCancer Biology

Low-dose lung radiotherapy for COVID-19 lung disease: a pre-clinical efficacy study in a bleomycin model of pneumonitis.

M. R. Jackson, K. Stevenson, S. K. Chahal, E. Curley, G. Finney, R. Gutierrez-Quintana, E. Onwubiko, A. F. Rupp, K. Strathdee, M. K. MacLeod, C. McSharry, A. J. Chalmers

This study evaluates low-dose lung radiotherapy (LDLR) in a bleomycin pneumonitis model, finding that 1.0 Gy LDLR improves recovery and reduces inflammation, particularly in moderate cases.

bioRxiv · Mar 3, 2021Immunology

Quantitative in vivo bioluminescence imaging of orthotopic patient-derived glioblastoma xenografts

A. L. Koessinger, D. Koessinger, K. Stevenson, C. Cloix, L. Mitchell, A. J. Chalmers, J. C. Norman, S. W. Tait

This paper demonstrates the use of iRFP expression in patient-derived glioblastoma cells for non-invasive, quantitative monitoring of tumor growth in vivo.

Scientific Reports · Sep 21, 2020Peer-reviewedCancer Biology